In patients with AF and COVID-19 who receive DOAC, 30-day mortality risk is similar for nirmatrelvir/ritonavir and RdRp inhibitors.
For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results